We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Cases · August 18, 2021

80 yo Woman With an ER+PR+HER2- Metastatic Invasive Ductal Carcinoma

Written by
Ana C. Sandoval Leon MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • luis betancourt

    Aug 19, 2021

    Fulvestrant/Everolimus


  • sw lee

    Aug 20, 2021

    Fulvestrant


  • roberto buonaiuto

    Aug 20, 2021

    Fulvestrant/everolimus


  • krassimir orechkov

    Aug 23, 2021

    I vote for capecitabine


  • Amir Azadi

    Aug 23, 2021

    Fulvestrant/Everolimus


  • Swapan Kumar   Nath

    Aug 24, 2021

    I do suggest fulvestrant


  • nagib khoury

    Sep 05, 2021

    fulvestrant and everolimus (tolerability issue to be considered)


  • Feng-Jen Chen

    Oct 15, 2021

    Fulvestrant/Everolimus


  • Jan 27, 2022

    Pending Moderator approval.
    Delete

Further Reading